Alzheimer’s disease (AD) is the most common form of dementia and biomarkers are essential to help in the diagnosis of this disease. Image techniques and cerebrospinal fluid (CSF) biomarkers are limited in their use because they are expensive or invasive. Thus, the search for blood-borne biomarkers is becoming central to the medical community.
Objective:
The main objective of this study is the evaluation of three serum proteins as potential biomarkers in AD patients.
Methods:
We recruited 27 healthy controls, 19 mild cognitive impairment patients, and 17 AD patients. Using the recent A/T/N classification we split our population into two groups (AD and control). We used ELISA kits to determine Aβ42, tau, and p-tau in CSF and clusterin, PKR, and RAGE in serum.
Results:
The levels of serum clusterin, PKR, and RAGE were statistically different in the AD group compared to controls. These proteins showed a statistically significant correlation with CSF Aβ42. So, they were selected to generate an AD detection model showing an AUC-ROC of 0.971 (CI 95%, 0.931–0.998).
Conclusion:
The developed model based on serum biomarkers and other co-variates could reflect the AD core pathology. So far, not one single blood-biomarker has been described, with effectiveness offering high sensitivity and specificity. We propose that the complexity of AD pathology could be reflected in a set of biomarkers also including clinical features of the patients.
TangY, LutzMW, XingY (2018) A systems-based model of Alzheimer’s disease. Alzheimers Dement15, 168–171.
11.
GrøntvedtGR, LauridsenC, BergeG, WhiteLR, ØyvindS, BrathenG, SandoSB (2020) The amyloid, tau, and neurodegeneration (A/T/N) classification applied to a clinical research cohort with long-term follow-up. J Alzheimers Dis74, 829–837.
12.
BurnhamSC, ColomaPM, LiQX, CollinsS, SavageG, LawsS, RoweCC (2019) Application of the NIA-AA research framework: Towards a biological definition of Alzheimer’s disease using cerebrospinal fluid biomarkers in the AIBL study. J Prev Alzheimers Dis6, 248–255.
13.
FosterEM, Dangla-VallsA, LovestoneS, RibeEM, BuckleyNJ (2019) Clusterin in Alzheimer’s disease: Mechanisms, genetics, and lessons from other pathologies. Front Neurosci13, 164.
14.
NarayanP, OrteA, ClarkeRW, BolognesiB, HookS, GanzingerKA, MeehanS, WilsonMR, DobsonCM, KlenermanD (2012) The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β 1–40 peptide. Nat Struct Mol Biol19, 79–83.
15.
CaleroM, RostagnoA, MatsubaraE, ZlokovicB, FrangioneB, GhisoJ (2000) Apolipoprotein J (clusterin) and Alzheimer’s disease. Microsc Res Tech50, 305–315.
16.
NuutinenT, SuuronenT, KauppinenA, SalminenA (2009) No diagnostic value of plasma clusterin in Alzheimer’s disease. Brain Res Rev61, 89–104.
17.
YerburyJJ, PoonS, MeehanS, ThompsonB, KumitaJR, DobsonCM, WilsonMR (2007) The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J21, 2312–2322.
18.
HaroldD, AbrahamR, HollingworthP, SimsR, GerrishA, HamshereML, PahwaJS, MoskvinaV, DowzellK, WilliamsA (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet41, 1088.
19.
SilajdžićE, MinthonL, BjörkqvistM, HanssonO (2012) No diagnostic value of plasma clusterin in Alzheimer’s disease. PLoS One7, e50237.
20.
ThambisettyM, SimmonsA, VelayudhanL, HyeA, CampbellJ, ZhangY, WahlundL, WestmanE, KinseyA, GüntertA (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry67, 739–748.
21.
IJsselstijnL, DekkerLJ, KoudstaalPJ, HofmanA, Sillevis SmittPA, BretelerMM, LuiderTM (2011) Serum clusterin levels are not increased in presymptomatic Alzheimer’s disease. J Proteome Res10, 2006–2010.
22.
SchrijversEM, KoudstaalPJ, HofmanA, BretelerMM (2011) Plasma clusterin and the risk of Alzheimer disease. JAMA305, 1322–1326.
23.
YuJ, TanL (2012) The role of clusterin in Alzheimer’s disease: Pathways, pathogenesis, and therapy. Mol Neurobiol45, 314–326.
24.
HaightT, BryanRN, MeirellesO, TracyR, FornageM, RichardM, NasrallahI, YaffeK, JacobsDRJr, LewisC (2018) Associations of plasma clusterin and Alzheimer’s disease-related MRI markers in adults at mid-life: The CARDIA Brain MRI sub-study. PLoS One13, e0190478.
25.
LiangH, RussellC, MitraV, ChungR, HyeA, BazenetC, LovestoneS, PikeI, WardM (2015) Glycosylation of human plasma clusterin yields a novel candidate biomarker of Alzheimer’s disease. J Proteome Res14, 5063–5076.
26.
SilverbergGD, MillerMC, MessierAA, MajmudarS, MachanJT, DonahueJE, StopaEG, JohansonCE (2010) Amyloid deposition and influx transporter expression at the blood-brain barrier increase in normal aging. J Neuropathol Exp Neurol69, 98–108.
27.
ZlokovicBV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron57, 178–201.
28.
DeaneR, Du YanS, SubmamaryanRK, LaRueB, JovanovicS, HoggE, WelchD, MannessL, LinC, YuJ (2003) RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med9, 907–913.
29.
DeaneR, WuZ, ZlokovicBV (2004) RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid β-peptide clearance through transport across the blood–brain barrier. Stroke35, 2628–2631.
30.
NelsonAR, SweeneyMD, SagareAP, ZlokovicBV (2016) Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer’s disease. Biochim Biophys Acta1862, 887–900.
31.
ZenaroE, PiacentinoG, ConstantinG (2017) The blood-brain barrier in Alzheimer’s disease. Neurobiol Dis107, 41–56.
32.
KongY, LiuC, ZhouY, QiJ, ZhangC, SunB, WangJ, GuanY (2020) Progress of RAGE molecular imaging in Alzheimer’s disease. Front Aging Neurosci12, 227.
33.
Du YanS, ChenX, FuJ, ChenM, ZhuH, RoherA, SlatteryT, ZhaoL, NagashimaM, MorserJ (1996) RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature382, 685.
34.
De StrooperB, KarranE (2016) The cellular phase of Alzheimer’s disease. Cell164, 603–615.
35.
KookS, Seok HongH, MoonM, Mook-JungI (2013) Disruption of blood-brain barrier in Alzheimer disease pathogenesis. Tissue Barriers1, 8845–8854.
36.
ZlokovicBV (2005) Neurovascular mechanisms of Alz-heimer’s neurodegeneration. Trends Neurosci28, 202–208.
37.
ArancioO, ZhangHP, ChenX, LinC, TrincheseF, PuzzoD, LiuS, HegdeA, YanSF, SternA (2004) RAGE potentiates Aβ-induced perturbation of neuronal function in transgenic mice. EMBO J23, 4096–4105.
38.
FengGS, ChongK, KumarA, WilliamsBR (1992) Identification of double-stranded RNA-binding domains in the interferon-induced double-stranded RNA-activated p68 kinase. Proc Natl Acad Sci U S A89, 5447–5451.
39.
Garcia-OrtegaMB, LopezGJ, JimenezG, Garcia-GarciaJA, CondeV, BoulaizH, CarrilloE, PeránM, MarchalJA, GarciaMA (2017) Clinical and therapeutic potential of protein kinase PKR in cancer and metabolism. Expert Rev Mol Med19.
40.
Gal-Ben-AriS, BarreraI, EhrlichM, RosenblumK (2019) PKR: A kinase to remember. Front Mol Neurosci11, 480.
41.
DumurgierJ, Mouton-LigerF, LapalusP, PrevotM, LaplancheJ, HugonJ, PaquetC, Groupe d’Investigation du Liquide Cephalorachidien (GIL) Study Network (2013) Cerebrospinal fluid PKR level predicts cognitive decline in Alzheimer’s disease. PLoS One8, e53587.
42.
ChangRC, SuenK, MaC, ElyamanW, NgH, HugonJ (2002) Involvement of double-stranded RNA-dependent protein kinase and phosphorylation of eukaryotic initiation factor-2α in neuronal degeneration. J Neurochem83, 1215–1225.
43.
HugonJ, Mouton-LigerF, DumurgierJ, PaquetC (2017) PKR involvement in Alzheimer’s disease. Alzheimers Res Ther9, 83.
44.
Mouton-LigerF, PaquetC, DumurgierJ, LapalusP, GrayF, LaplancheJ, HugonJ, Groupe d’Investigation du Liquide Céphalorachidien Study Network (2012) Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer’s disease. Biol Psychiatry71, 829–835.
45.
PaccalinM, Pain-BarcS, PluchonC, PaulC, BessonM, Carret-RebillatA, Rioux-BilanA, GilR, HugonJ (2006) Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer’s disease. Dement Geriatr Cogn Disord22, 320–326.
46.
BadiaM, LloretA, GiraldoE, DasiF, OlasoG, AlonsoM, VinaJ (2013) Lymphocytes from young healthy persons carrying the ApoE4 allele overexpress stress-related proteins involved in the pathophysiology of Alzheimer’s disease. J Alzheimers Dis33, 77–83.
47.
DuboisB, FeldmanHH, JacovaC, DeKoskyST, Barberger-GateauP, CummingsJ, DelacourteA, GalaskoD, GauthierS, JichaG, MeguroK, O’BrienJ, PasquierF, RobertP, RossorM, SallowayS, SternY, VisserPJ, ScheltensP (2007) Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS–ADRDA criteria. Lancet Neurol6, 734–746.
48.
PetersenRC, DoodyR, KurzA, MohsRC, MorrisJC, RabinsPV, RitchieK, RossorM, ThalL, WinbladB (2001) Current concepts in mild cognitive impairment. Arch Neurol58, 1985–1992.
49.
LoboA, SazP, MarcosG, DíaJL, de la CámaraC, VenturaT, Morales AsínF, Fernando PascualL, MontañésJÁ, AznarS (1999) Revalidación y normalización del Mini-Examen Cognoscitivo (primera versión en castellano del Mini-Mental Status Examination) en la población general geriátrica. Med Clin112, 767–774.
50.
JonesN (2010) Plasma clusterin predicts degree of pathogenesis in AD. Nat Rev Neurol6, 469.
51.
VishnuVY, ModiM, SharmaS, MohantyM, GoyalMK, LalV, KhandelwalN, MittalBR, PrabhakarS (2016) Role of plasma clusterin in Alzheimer’s disease—a pilot study in a tertiary hospital in Northern India. PLoS One11, e0166369.
52.
JongbloedW, van DijkKD, MulderSD, van de Berg, WilmaDJ, BlankensteinMA, van der FlierW, VeerhuisR (2015) Clusterin levels in plasma predict cognitive decline and progression to Alzheimer’s disease. J Alzheimers Dis46, 1103–1110.
53.
GuptaVB, DoeckeJD, HoneE, PedriniS, LawsSM, ThambisettyM, BushAI, RoweCC, VillemagneVL, AmesD (2016) Plasma apolipoprotein J as a potential biomarker for Alzheimer’s disease: Australian Imaging, Biomarkers and Lifestyle study of aging. Alzheimers Dement (Amst)3, 18–26.
54.
DonahueJE, FlahertySL, JohansonCE, DuncanJA, SilverbergGD, MillerMC, TavaresR, YangW, WuQ, SaboE (2006) RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol112, 405–415.
55.
GerardI, PalomerE, WozniakMA, Ramos-FernándezE, Bosch-MoratóM, TajesM, GuixFX, GalánJJ, ClarimónJ, AntúnezC (2011) Activation of PKR causes amyloid ß-peptide accumulation via de-repression of BACE1 expression. PLoS One6, e21456.
56.
VerberkIM, ThijssenE, KoelewijnJ, MaurooK, VanbrabantJ, De WildeA, ZwanMD, VerfaillieSC, OssenkoppeleR, BarkhofF (2020) Combination of plasma amyloid beta (1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther12, 1–14.
57.
ShiY, LuX, ZhangL, ShuH, GuL, WangZ, GaoL, ZhuJ, ZhangH, ZhouD (2019) Potential value of plasma amyloid-β, total Tau, and neurofilament light for identification of early Alzheimer’s disease. ACS Chem Neurosci10, 3479–3485.
58.
RobbMA, McInnesPM, CaliffRM (2016) Biomarkers and surrogate endpoints: Developing common terminology and definitions. JAMA315, 1107–1108.
59.
WhileyL, SenA, HeatonJ, ProitsiP, García-GómezD, LeungR, SmithN, ThambisettyM, KloszewskaI, MecocciP (2014) Evidence of altered phosphatidylcholine metabolism in Alzheimer’s disease. Neurobiol Aging35, 271–278.
60.
ProitsiP, KimM, WhileyL, SimmonsA, SattleckerM, VelayudhanL, LuptonMK, SoininenH, KloszewskaI, MecocciP (2017) Association of blood lipids with Alzheimer’s disease: A comprehensive lipidomics analysis. Alzheimers Demen13, 140–151.
61.
KosicekM, HecimovicS (2013) Phospholipids and Alzheimer’s disease: Alterations, mechanisms and potential biomarkers. Int J Mol Sci14, 1310–1322.
MattssonN, ZetterbergH, JanelidzeS, InselPS, AndreassonU, StomrudE, PalmqvistS, BakerD, HehirCAT, JerominA (2016) Plasma tau in Alzheimer disease. Neurology87, 1827–1835.
65.
MielkeMM, HagenCE, XuJ, ChaiX, VemuriP, LoweVJ, AireyDC, KnopmanDS, RobertsRO, MachuldaMM (2018) Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau-and amyloid-positron emission tomography. Alzheimers Dement14, 989–997.
66.
LewczukP, ErmannN, AndreassonU, SchultheisC, PodhornaJ, SpitzerP, MalerJM, KornhuberJ, BlennowK, ZetterbergH (2018) Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease. Alzheimers Res Ther10, 71.
67.
MattssonN, AndreassonU, ZetterbergH, BlennowK (2017) Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol74, 557–566.
68.
ZetterbergH, WilsonD, AndreassonU, MinthonL, BlennowK, RandallJ, HanssonO (2013) Plasma tau levels in Alzheimer’s disease. Alzheimers Res Ther5, 1–3.
OecklP, HalbgebauerS, Anderl-StraubS, SteinackerP, HussAM, NeugebauerH, von ArnimCA, Diehl-SchmidJ, GrimmerT, KornhuberJ (2019) Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment. J Alzheimers Dis67, 481–488.
71.
IshikiA, KamadaM, KawamuraY, TeraoC, ShimodaF, TomitaN, AraiH, FurukawaK (2016) Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem136, 258–261.
